This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Press Release Date: August 17, 2006
Difficulties in diagnosing anthrax may lead to dangerous delays in caring for children infected with this often-deadly disease, according to a new report from HHS' Agency for Healthcare Research and Quality (AHRQ). Treating pediatric anthrax is also a special challenge because most currently recommended therapies have not been widely used to treat children with the disease. The anthrax report was requested and funded by HHS' Health Resources and Services Administration.
Since anthrax exposure occurs rarely in the United States and most of the recent cases have been naturally occurring, clinicians may not have first-hand knowledge about the disease and might have difficulty diagnosing it. In addition, symptoms of pediatric anthrax can be easily confused with those of more common illnesses; for example, inhalational anthrax has symptoms similar to influenza. Also, there is little evidence about the effectiveness in children of interventions currently recommended for adults.
"This report provides important information for dealing with exposure of children to anthrax," said AHRQ Director Carolyn M. Clancy, M.D. "It analyzes what is currently known about how this terrible disease affects children and identifies research needed to make us more effective in protecting our children from anthrax."
The researchers found very little published evidence about the efficacy of treating children who have anthrax with newer antibiotics such as ciprofloxacin. They also found no reports of using anthrax vaccine for children. The report calls for more current research on the effectiveness in children of non-antibiotic therapies that have been used with considerable success in the past, such as anthrax antiserum and drainage of fluid from the lung cavity.
Anthrax typically is contracted by direct contact with a bacterium found in infected farm animals and usually is not transmissible from one person to another. The three principal types of anthrax are cutaneous (contracted through cuts in the skin), gastrointestinal (ingested from infected meat), and inhalational (breathed in through the lungs). The most widely reported recent cases of anthrax in the United States followed the introduction of bacterial spores into the U.S. mail system in 2001, which resulted in five deaths among 22 cases.
For the new AHRQ report, investigators analyzed 62 pediatric cases obtained through an extensive review of the scientific literature. Because case reports of pediatric anthrax are relatively rare, investigators examined cases from as early as 1900 in an effort to maximize the available evidence. More than 50 percent involved children between the ages of 14 and 18; data on younger children, especially those under age 2, were more limited. There were only two cases of inhalational anthrax, the most deadly form of the disease.
The AHRQ report, Pediatric Anthrax: Implications
for Bioterrorism Preparedness was prepared by AHRQ's Evidence-based Practice Center at Stanford University and the University of California, San Francisco.
Print copies are available by calling the AHRQ Publications Clearinghouse at 800-358-9295 or by sending an E-mail to email@example.com. Related studies by the EPC include "Systematic Review: A Century of Inhalational Anthrax Cases from 1900 to 2005," which appeared in the February 21, 2006, issue of Annals of Internal Medicine and "Anthrax: A Systematic Review of Atypical Presentations," which appears in the August 2006 issue of the Annals of Emergency Medicine.
For more information, please contact AHRQ Public Affairs: (301) 427-1241 or (301) 427-1855.